Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

Per Olov Hedlund; Martti Ala-Opas; Einar Brekkan; Jan Erik Damber; Lena Damber; Inger Hagerman; Svein Haukaas; Peter Henriksson; Peter Iversen; Ake Pousette; Finn Rasmussen; Jaakko Salo; Sigmund Vaage; Eberhard Varenhorst; Scandinavian Prostatic Cancer Group

doi:10.1080/003655902762467549

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

Per Olov Hedlund, Martti Ala-Opas, Einar Brekkan, Jan Erik Damber, Lena Damber, Inger Hagerman, Svein Haukaas, Peter Henriksson, Peter Iversen, Ake Pousette, Finn Rasmussen, Jaakko Salo, Sigmund Vaage, Eberhard Varenhorst, Scandinavian Prostatic Cancer Group

49 Citations (Scopus)

Abstract

In the mid-1980s, interest in parenteral estrogen therapy for prostate cancer was renewed when it was found that it influenced liver metabolism only marginally and had very few cardiovascular side-effects. In this study high-dose polyestradiol phosphate (PEP; Estradurin) was compared to combined androgen deprivation (CAD) for the treatment of patients with metastatic prostate cancer. The aim of the study was to compare anticancer efficacy and adverse events, especially cardiovascular side-effects.

Original language	English
Journal	Scandinavian Journal of Urology and Nephrology
Volume	36
Issue number	6
Pages (from-to)	405-13
Number of pages	9
ISSN	0036-5599
DOIs	https://doi.org/10.1080/003655902762467549
Publication status	Published - 1 Jan 2002

Access to Document

10.1080/003655902762467549

Cite this

Hedlund, P. O., Ala-Opas, M., Brekkan, E., Damber, J. E., Damber, L., Hagerman, I., Haukaas, S., Henriksson, P., Iversen, P., Pousette, A., Rasmussen, F., Salo, J., Vaage, S., Varenhorst, E., & Scandinavian Prostatic Cancer Group (2002). Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scandinavian Journal of Urology and Nephrology, 36(6), 405-13. https://doi.org/10.1080/003655902762467549

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. / Hedlund, Per Olov; Ala-Opas, Martti; Brekkan, Einar et al.
In: Scandinavian Journal of Urology and Nephrology, Vol. 36, No. 6, 01.01.2002, p. 405-13.

Research output: Contribution to journal › Journal article › Research

Hedlund, PO, Ala-Opas, M, Brekkan, E, Damber, JE, Damber, L, Hagerman, I, Haukaas, S, Henriksson, P, Iversen, P, Pousette, A, Rasmussen, F, Salo, J, Vaage, S, Varenhorst, E & Scandinavian Prostatic Cancer Group 2002, 'Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5', Scandinavian Journal of Urology and Nephrology, vol. 36, no. 6, pp. 405-13. https://doi.org/10.1080/003655902762467549

@article{abac3473bdc84d5db475ecb89f1fd9c2,

title = "Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5",

abstract = "In the mid-1980s, interest in parenteral estrogen therapy for prostate cancer was renewed when it was found that it influenced liver metabolism only marginally and had very few cardiovascular side-effects. In this study high-dose polyestradiol phosphate (PEP; Estradurin) was compared to combined androgen deprivation (CAD) for the treatment of patients with metastatic prostate cancer. The aim of the study was to compare anticancer efficacy and adverse events, especially cardiovascular side-effects.",

author = "Hedlund, \{Per Olov\} and Martti Ala-Opas and Einar Brekkan and Damber, \{Jan Erik\} and Lena Damber and Inger Hagerman and Svein Haukaas and Peter Henriksson and Peter Iversen and Ake Pousette and Finn Rasmussen and Jaakko Salo and Sigmund Vaage and Eberhard Varenhorst and \{Scandinavian Prostatic Cancer Group\}",

year = "2002",

month = jan,

day = "1",

doi = "10.1080/003655902762467549",

language = "English",

volume = "36",

pages = "405--13",

journal = "Scandinavian Journal of Urology and Nephrology",

issn = "0036-5599",

publisher = "Taylor \& Francis",

number = "6",

}

TY - JOUR

T1 - Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

AU - Hedlund, Per Olov

AU - Ala-Opas, Martti

AU - Brekkan, Einar

AU - Damber, Jan Erik

AU - Damber, Lena

AU - Hagerman, Inger

AU - Haukaas, Svein

AU - Henriksson, Peter

AU - Iversen, Peter

AU - Pousette, Ake

AU - Rasmussen, Finn

AU - Salo, Jaakko

AU - Vaage, Sigmund

AU - Varenhorst, Eberhard

AU - Scandinavian Prostatic Cancer Group

PY - 2002/1/1

Y1 - 2002/1/1

N2 - In the mid-1980s, interest in parenteral estrogen therapy for prostate cancer was renewed when it was found that it influenced liver metabolism only marginally and had very few cardiovascular side-effects. In this study high-dose polyestradiol phosphate (PEP; Estradurin) was compared to combined androgen deprivation (CAD) for the treatment of patients with metastatic prostate cancer. The aim of the study was to compare anticancer efficacy and adverse events, especially cardiovascular side-effects.

AB - In the mid-1980s, interest in parenteral estrogen therapy for prostate cancer was renewed when it was found that it influenced liver metabolism only marginally and had very few cardiovascular side-effects. In this study high-dose polyestradiol phosphate (PEP; Estradurin) was compared to combined androgen deprivation (CAD) for the treatment of patients with metastatic prostate cancer. The aim of the study was to compare anticancer efficacy and adverse events, especially cardiovascular side-effects.

UR - https://www.scopus.com/pages/publications/0036973520

U2 - 10.1080/003655902762467549

DO - 10.1080/003655902762467549

M3 - Journal article

C2 - 12623503

SN - 0036-5599

VL - 36

SP - 405

EP - 413

JO - Scandinavian Journal of Urology and Nephrology

JF - Scandinavian Journal of Urology and Nephrology

IS - 6

ER -

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

Abstract

Access to Document

Other files and links

Fingerprint

Cite this